Jessica Scanlon, MD
Dermatology · Boston, MANPI 1689833857
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $637, 3.8 times the $167 reported in 2019.
Across 67 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$340
- Lilly USA, LLC$230
- Sanofi$190
- Novartis$171
- Galderma Laboratories, L.p.$153
- UCB, Inc.$95
- plus $454 from 12 others
What the payments were for
- Food & beverage$1,634100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $340 |
| Lilly USA, LLC | 10 | $230 |
| Sanofi | 8 | $190 |
| Novartis | 8 | $171 |
| Galderma Laboratories, L.p. | 2 | $153 |
| UCB, Inc. | 4 | $95 |
| Organon | 4 | $92 |
| Pfizer | 3 | $66 |
| Incyte Corporation | 3 | $64 |
| Johnson & Johnson | 2 | $40 |
| Dermavant Sciences, Inc. | 2 | $39 |
| Sun Pharmaceutical Industries Inc. | 1 | $30 |
| Amgen | 1 | $24 |
| Verrica Pharmaceuticals Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $17 |
| LNHC, Inc | 1 | $15 |
How this compares
$1,634 in reported general payments places this provider in the 55th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $60,853 |
| Clobetasol Propionate | 62 | $5,154 |
| Metronidazole | 58 | $2,664 |
| Econazole Nitrate | 30 | $1,506 |
| Fluorouracil | 20 | $1,412 |
| Betamethasone Dipropionate | 16 | $1,300 |
| Clindamycin Phosphate | 32 | $1,204 |
| Ketoconazole | 47 | $1,161 |
| Fluocinolone Acetonide | 26 | $1,031 |
| Triamcinolone Acetonide | 101 | $987 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 13 | $930 |
| Mupirocin | 64 | $779 |
| Doxycycline Monohydrate | 22 | $350 |
| CiclopiroxCiclopirox Olamine | 18 | $326 |
| Halobetasol Propionate | 12 | $285 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Boston
- Alexandra KimballBoston$680K
- Arash MostaghimiBoston$591K
- Brian HiblerBoston$498K
- Maryanne SennaBoston$430K
- Ruth Ann VleugelsBoston$368K
- Gabriela CobosBoston$343K
- Martina PorterBoston$220K
- Mathew AvramBoston$209K
- Emmy GraberBoston$159K
- Neelam VashiBoston$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.